Dynavax Technologies Corporation(DVAX)Earnings, Financials & Key Ratios

DVAX•NASDAQ

$15.50

$1.82B mkt cap·77.5× P/E·Price updated Apr 24, 2026

SectorHealthcare IndustrySpecialty & Generic Pharma Sub-IndustryVaccines and biodefense products

AboutDynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.Show more

Revenue$277M+19.4%
EBITDA$4M+113.2%
Net Income$27M+527.4%
EPS (Diluted)0.20+503.2%
Gross Margin82.17%+4.8%
EBITDA Margin1.42%+111.1%
Operating Margin-1.49%+90.7%
Net Margin9.85%+458.1%
ROE4.48%+521.9%
ROIC-0.42%+89.8%
Debt/Equity0.43+3.2%
Interest Coverage-0.61+88.9%

Technical→

DVAX Key Insights

Dynavax Technologies Corporation (DVAX) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 25.5%
✓FCF machine: 21.7% free cash flow margin
✓Momentum leader: RS Rating 89 (top 11%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 51.1%
✓Trading near 52-week high

✗Weaknesses

✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

DVAX Price & Volume

Dynavax Technologies Corporation (DVAX) stock price & volume — 10-year historical chart

Loading chart...

DVAX Growth Metrics

Dynavax Technologies Corporation (DVAX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years38.05%

5 Years51.08%

3 Years-14.23%

TTM26.73%

Profit CAGR

10 Years-

5 Years-

3 Years-29.13%

TTM-311.94%

EPS CAGR

10 Years-

5 Years-

3 Years-29.47%

TTM-395.34%

Return on Capital

10 Years-32.07%

5 Years8.77%

3 Years12.79%

Last Year-0.45%

DVAX Recent Earnings

Dynavax Technologies Corporation (DVAX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 7/12 qtrs (58%)●Beat Revenue 7/12 qtrs (64%)

Q1 2026Latest

Feb 19, 2026

EPS

$0.05

Est $0.08

-38.5%

Revenue

—

Est $82M

Q4 2025

Nov 5, 2025

EPS

$0.21

Est $0.14

+50.0%

Revenue

$95M

Est $80M

+18.2%

Q3 2025

Aug 7, 2025

EPS

$0.14

Est $0.12

+16.7%

Revenue

$95M

Est $94M

+1.5%

Q2 2025

May 6, 2025

EPS

$0.11

Est $0.03

-466.7%

Revenue

$68M

Est $84M

-19.0%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 19, 2026	$0.05vs $0.08-38.5%	—vs $82M
Q4 2025	Nov 5, 2025	$0.21vs $0.14+50.0%	$95Mvs $80M+18.2%
Q3 2025	Aug 7, 2025	$0.14vs $0.12+16.7%	$95Mvs $94M+1.5%
Q2 2025	May 6, 2025	$0.11vs $0.03-466.7%	$68Mvs $84M-19.0%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
NVAXNovavax, Inc.Direct Competitor	1.53B	9.36	3.69	64.69%	-14.73%
SIGASIGA Technologies, Inc.Direct Competitor	336.57M	4.70	14.24	-31.8%	24.64%	0%	0
IMVTImmunovant, Inc.Direct Competitor	5.83B	28.67	-10.50			-47.07%	0.00
VXRTVaxart, Inc.Direct Competitor	179.17M	0.75	10.64	7.27%	6.88%	33.83%	0.10
IBRXImmunityBio, Inc.Direct Competitor	8.25B	8.38	-13.52	22.71%	-422.28%
PFEPfizer Inc.Product Competitor	150.77B	26.51	19.49	-1.65%	11.83%	8.34%	0.78
MRKMerck & Co., Inc.Product Competitor	280.48B	113.56	15.60	1.18%	28.12%	36.14%	0.96
GSKGSK plcProduct Competitor	101.62B	50.53	6.69	4.11%	19.19%	31.48%	1.11

Compare DVAX vs Peers

Dynavax Technologies Corporation (DVAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVAX

Most directly comparable listed peer for DVAX.

Scale Benchmark

vs MRK

Larger-name benchmark to compare DVAX against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVAX, SIGA, IMVT, VXRT

DVAX Income Statement

Dynavax Technologies Corporation (DVAX) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	TTM
Sales/Revenue	11.04M	327K	8.2M	35.22M	46.55M	439.44M	722.68M	232.28M	277.25M	330.51M
Revenue Growth %	172.67%	-97.04%	2407.03%	329.6%	32.18%	844%	64.45%	-67.86%	19.36%	26.73%
Cost of Goods Sold	0	1.19M	21.8M	19.39M	13.91M	173.57M	262.15M	50.17M	49.45M	55.62M
COGS % of Revenue	-	365.14%	265.87%	55.05%	29.88%	39.5%	36.27%	21.6%	17.83%	-
Gross Profit	11.04M▲ 0%	-867K▼ 107.9%	-13.6M▼ 1468.4%	15.83M▲ 216.4%	32.64M▲ 106.2%	265.87M▲ 714.5%	460.53M▲ 73.2%	182.12M▼ 60.5%	227.8M▲ 25.1%	274.9M▲ 0%
Gross Margin %	100%	-265.14%	-165.87%	44.95%	70.12%	60.5%	63.73%	78.4%	82.17%	83.17%
Gross Profit Growth %	172.67%	-107.85%	-1468.4%	216.41%	106.2%	714.53%	73.22%	-60.45%	25.09%	-
Operating Expenses	121.75M	93.55M	139.72M	150.67M	107.86M	131.38M	177.01M	219.15M	231.92M	264.46M
OpEx % of Revenue	1102.51%	28608.26%	1704.33%	427.82%	231.71%	29.9%	24.49%	94.34%	83.65%	-
Selling, General & Admin	37.26M	27.37M	64.77M	74.99M	79.26M	100.16M	131.41M	152.95M	170.37M	179.71M
SG&A % of Revenue	337.38%	8369.11%	790.07%	212.91%	170.26%	22.79%	18.18%	65.84%	61.45%	-
Research & Development	84.49M	64.99M	74.95M	62.33M	28.61M	32.23M	46.6M	54.89M	61.55M	73.78M
R&D % of Revenue	765.13%	19874.01%	914.26%	176.98%	61.45%	7.33%	6.45%	23.63%	22.2%	-
Other Operating Expenses	0	-486K	-70K	13.36M	0	-1M	-1M	11.31M	0	1000K
Operating Income	-110.71M▲ 0%	-96M▲ 13.3%	-153.32M▼ 59.7%	-134.84M▲ 12.1%	-75.22M▲ 44.2%	134.49M▲ 278.8%	283.52M▲ 110.8%	-37.03M▼ 113.1%	-4.12M▲ 88.9%	10.44M▲ 0%
Operating Margin %	-1002.51%	-29359.33%	-1870.2%	-382.87%	-161.59%	30.6%	39.23%	-15.94%	-1.49%	3.16%
Operating Income Growth %	-5.36%	13.28%	-59.7%	12.05%	44.22%	278.79%	110.82%	-113.06%	88.87%	-
EBITDA	-108.45M	-91.57M	-138.84M	-113.31M	-65.89M	141.54M	290.19M	-29.75M	3.93M	18.68M
EBITDA Margin %	-982.07%	-28002.14%	-1693.53%	-321.74%	-141.54%	32.21%	40.15%	-12.81%	1.42%	5.65%
EBITDA Growth %	-4.57%	15.57%	-51.62%	18.38%	41.85%	314.83%	105.02%	-110.25%	113.21%	957.18%
D&A (Non-Cash Add-back)	2.26M	4.44M	14.48M	21.53M	9.34M	7.06M	6.67M	7.28M	8.05M	8.24M
EBIT	-112.44M	-95.15M	-149.56M	-135.62M	-56.18M	88.7M	301.03M	2.39M	37.65M	-33.89M
Net Interest Income	755K	1.34M	-5.51M	-13.61M	-17.8M	-11.04M	1.18M	25.24M	29.67M	23.13M
Interest Income	755K	1.34M	3.83M	3.37M	1.26M	140K	7.91M	31.99M	36.46M	29.54M
Interest Expense	0	0	9.34M	16.98M	19.06M	11.18M	6.73M	6.76M	6.79M	6.41M
Other Income/Expense	-1.74M	851K	-5.58M	-17.76M	-18K	-56.97M	10.78M	32.66M	34.98M	-51.05M
Pretax Income	-112.44M▲ 0%	-95.15M▲ 15.4%	-158.9M▼ 67.0%	-152.6M▲ 4.0%	-75.24M▲ 50.7%	77.52M▲ 203.0%	294.3M▲ 279.6%	-4.37M▼ 101.5%	30.86M▲ 806.5%	-40.61M▲ 0%
Pretax Margin %	-1018.24%	-29099.08%	-1938.27%	-433.29%	-161.63%	17.64%	40.72%	-1.88%	11.13%	-12.29%
Income Tax	0	0	0	0	0	808K	1.14M	2.02M	3.55M	2.79M
Effective Tax Rate %	0%	0%	0%	0%	0%	1.04%	0.39%	-46.3%	11.49%	-6.87%
Net Income	-112.44M▲ 0%	-95.15M▲ 15.4%	-158.9M▼ 67.0%	-152.6M▲ 4.0%	-75.24M▲ 50.7%	76.71M▲ 202.0%	293.16M▲ 282.1%	-6.39M▼ 102.2%	27.31M▲ 527.4%	-43.4M▲ 0%
Net Margin %	-1018.24%	-29099.08%	-1938.27%	-433.29%	-161.63%	17.46%	40.56%	-2.75%	9.85%	-13.13%
Net Income Growth %	-5.29%	15.38%	-66.99%	3.96%	50.69%	201.96%	282.15%	-102.18%	527.44%	-311.94%
Net Income (Continuing)	-112.44M	-95.15M	-158.9M	-152.6M	-75.24M	76.71M	293.16M	-6.39M	27.31M	-43.4M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-2.92▲ 0%	-1.81▲ 38.0%	-2.55▼ 40.9%	-2.10▲ 17.6%	-0.78▲ 62.9%	0.57▲ 173.1%	1.97▲ 245.6%	-0.05▼ 102.5%	0.20▲ 503.2%	-0.32▲ 0%
EPS Growth %	10.15%	38.01%	-40.88%	17.65%	62.86%	173.08%	245.61%	-102.52%	503.23%	-395.34%
EPS (Basic)	-2.92	-1.81	-2.55	-2.10	-0.75	0.62	2.32	-0.05	0.21	-
Diluted Shares Outstanding	38.51M	52.61M	62.36M	72.02M	100.75M	133.01M	150.8M	128.73M	133.34M	136.47M
Basic Shares Outstanding	38.51M	52.61M	62.36M	72.02M	100.75M	116.26M	126.4M	128.73M	130.05M	117.31M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

DVAX Balance Sheet

Dynavax Technologies Corporation (DVAX) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	TTM
Total Current Assets	81.42M	191.85M	164.56M	208.65M	290.01M	972.52M	916.99M	859.12M	848.94M	814.33M
Cash & Short-Term Investments	81.42M	191.85M	145.54M	151.06M	165.04M	545.95M	624.39M	742.3M	713.83M	647.82M
Cash Only	24.29M	26.58M	49.35M	39.88M	32.07M	436.19M	202M	150.28M	95.88M	160.25M
Short-Term Investments	57.13M	165.27M	96.19M	111.17M	132.96M	109.76M	422.39M	592.02M	617.95M	487.57M
Accounts Receivable	1.34M	854K	3.7M	8.89M	22.66M	131.82M	147.51M	44.53M	46.91M	73.32M
Days Sales Outstanding	44.36	953.24	164.91	92.09	177.68	109.49	74.5	69.98	61.75	69.06
Inventory	-8.18M	312K	19.02M	41.33M	63.69M	61.34M	59.45M	53.29M	70.05M	73.29M
Days Inventory Outstanding	-	95.38	318.55	778.08	1.67K	128.98	82.77	387.72	517.13	481.43
Other Current Assets	6.84M	1.31M	6.1M	0	0	73.76M	85.63M	19M	18.15M	19.91M
Total Non-Current Assets	28.27M	26.93M	46.33M	70.42M	63.26M	66.73M	68.86M	137.98M	137.31M	132.18M
Property, Plant & Equipment	17.17M	16.62M	17.06M	62.27M	57.15M	60.98M	63.34M	61.58M	60.61M	65.76M
Fixed Asset Turnover	0.64x	0.02x	0.48x	0.57x	0.81x	7.21x	11.41x	3.77x	4.57x	5.16x
Goodwill	1.97M	2.24M	2.14M	2.08M	2.3M	2.13M	2.01M	2.07M	1.95M	2.2M
Intangible Assets	0	0	11.72M	2.5M	0	0	0	0	0	0
Long-Term Investments	602K	629K	619K	0	0	0	0	0	71.58M	305K
Other Non-Current Assets	9.12M	8.07M	15.4M	3.56M	3.81M	3.62M	3.52M	74.33M	3.18M	267.07M
Total Assets	109.68M▲ 0%	218.78M▲ 99.5%	210.88M▼ 3.6%	279.07M▲ 32.3%	353.27M▲ 26.6%	1.04B▲ 194.2%	985.85M▼ 5.1%	997.1M▲ 1.1%	986.26M▼ 1.1%	946.51M▲ 0%
Asset Turnover	0.10x	0.00x	0.04x	0.13x	0.13x	0.42x	0.73x	0.23x	0.28x	0.35x
Asset Growth %	-49.37%	99.48%	-3.61%	32.33%	26.59%	194.18%	-5.14%	1.14%	-1.09%	-25.71%
Total Current Liabilities	20.04M	18.59M	38.03M	53.05M	77.41M	556.4M	150.07M	62.2M	78.63M	106.84M
Accounts Payable	3.8M	4.54M	5.28M	9.28M	3.31M	2.6M	3.21M	5.25M	9.06M	3.95M
Days Payables Outstanding	-	1.39K	88.39	174.66	86.91	5.47	4.47	38.16	66.89	32.88
Short-Term Debt	0	0	0	0	0	0	0	0	4.17M	40.07M
Deferred Revenue (Current)	0	0	0	0	38.21M	349.86M	0	0	0	0
Other Current Liabilities	0	0	24.7M	24.85M	10.74M	18.03M	0	24K	22K	4.23M
Current Ratio	4.06x	10.32x	4.33x	3.93x	3.75x	1.75x	6.11x	13.81x	10.80x	10.80x
Quick Ratio	4.47x	10.30x	3.83x	3.15x	2.92x	1.64x	5.71x	12.96x	9.91x	9.91x
Cash Conversion Cycle	-	-338.93	395.07	695.51	1.76K	233	152.8	419.54	512	517.61
Total Non-Current Liabilities	20.48M	19.24M	109.79M	217.73M	217.17M	260.47M	254.76M	312.83M	310.82M	305.53M
Long-Term Debt	0	0	100.87M	178.6M	179.81M	220.49M	221.58M	222.7M	223.85M	220.97M
Capital Lease Obligations	0	0	0	37.84M	34.79M	34.32M	32.8M	29.72M	26.39M	100.62M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	20.48M	643K	8.91M	1.28M	2.57M	5.66M	384K	60.41M	60.58M	242.32M
Total Liabilities	20.48M	19.24M	147.82M	270.78M	294.58M	816.87M	404.84M	375.02M	389.46M	412.37M
Total Debt	0	0	100.87M	216.45M	217.85M	257.38M	258.01M	256.91M	254.42M	285.02M
Net Debt	-24.29M	-26.58M	51.52M	176.56M	185.77M	-178.81M	56.01M	106.64M	158.53M	124.78M
Debt / Equity	-	-	1.60x	26.11x	3.71x	1.16x	0.44x	0.41x	0.43x	0.43x
Debt / EBITDA	-	-	-	-	-	1.82x	0.89x	-	64.74x	15.26x
Net Debt / EBITDA	-	-	-	-	-	-1.26x	0.19x	-	40.34x	40.34x
Interest Coverage	-	-	-16.42x	-7.94x	-3.95x	12.03x	42.12x	-5.48x	-0.61x	-5.28x
Total Equity	89.2M▲ 0%	199.55M▲ 123.7%	63.06M▼ 68.4%	8.29M▼ 86.9%	58.69M▲ 608.0%	222.37M▲ 278.9%	581.01M▲ 161.3%	622.07M▲ 7.1%	596.8M▼ 4.1%	534.14M▲ 0%
Equity Growth %	-52.32%	123.71%	-68.4%	-86.85%	608%	278.88%	161.28%	7.07%	-4.06%	-62.96%
Book Value per Share	2.32	3.79	1.01	0.12	0.58	1.67	3.85	4.83	4.48	3.91
Total Shareholders' Equity	89.2M	199.55M	63.06M	8.29M	58.69M	222.37M	581.01M	622.07M	596.8M	534.14M
Common Stock	39K	62K	63K	84K	110K	123K	128K	130K	125K	117K
Retained Earnings	-812.17M	-907.33M	-1.07B	-1.22B	-1.29B	-1.22B	-924.2M	-930.58M	-903.27M	-953.73M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3.62M	-881K	-2.02M	-2.39M	273K	-2.27M	-5.44M	-2.11M	-4.72M	800K
Minority Interest	0	0	0	0	0	0	0	0	0	0

DVAX Cash Flow Statement

Dynavax Technologies Corporation (DVAX) cash flow — operating, investing & free cash flow history

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	TTM
Cash from Operations	-107.05M	-77.52M	-131.3M	-121.25M	-92.25M	335.53M	62.72M	100.56M	66.51M	66.51M
Operating CF Margin %	-969.4%	-23705.81%	-1601.62%	-344.28%	-198.17%	76.35%	8.68%	43.29%	23.99%	-
Operating CF Growth %	-15.66%	27.59%	-69.38%	7.65%	23.92%	463.71%	-81.31%	60.35%	-33.86%	459.83%
Net Income	-112.44M	-95.15M	-158.9M	-152.6M	-75.24M	76.71M	293.16M	-6.39M	27.31M	-43.4M
Depreciation & Amortization	2.26M	4.44M	14.48M	21.53M	9.34M	7.06M	6.67M	7.28M	8.05M	8.24M
Stock-Based Compensation	14.13M	14.92M	23.48M	25.46M	13.48M	21.29M	32.91M	42.59M	52.62M	52.83M
Deferred Taxes	1.13M	-203K	-1.46M	6.06M	0	0	61.77M	-5.24M	0	0
Other Non-Cash Items	602K	-209K	2.75M	11.97M	-6.92M	58.25M	-33.38M	1.12M	-5.43M	90.65M
Working Capital Changes	-12.72M	-1.31M	-11.66M	-33.67M	-32.91M	172.22M	-298.42M	61.21M	-16.04M	-17.68M
Change in Receivables	52K	52K	7.34M	-17.84M	-13.78M	-109.16M	-15.7M	43.27M	-2.37M	1.96M
Change in Inventory	-11.2M	-312K	-18.71M	-22.31M	-22.36M	-234K	-32.4M	3.91M	-19.91M	-16.41M
Change in Payables	1.18M	-1.92M	3.42M	4.85M	-3.45M	-767K	691K	1.95M	3.9M	-3.27M
Cash from Investing	86.25M	-108.7M	55.47M	-42.78M	-26.53M	14.22M	-316M	-153.93M	-18.04M	152.39M
Capital Expenditures	-7.76M	-669K	-15.19M	-29.4M	-4.07M	-9.48M	-7.14M	-4.1M	-6.35M	-10.1M
CapEx % of Revenue	70.24%	204.59%	185.25%	83.48%	8.75%	2.16%	0.99%	1.77%	2.29%	-
Acquisitions	0	0	11M	7M	0	0	1M	1M	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-11M	-7M	-149K	1M	0	0	0	0
Cash from Financing	531K	187.84M	99.07M	154.35M	109.5M	55.78M	19.52M	1.39M	-102.02M	-202.74M
Debt Issued (Net)	0	0	99M	74.25M	0	29.63M	0	0	0	-41.79M
Equity Issued (Net)	0	1000K	0	1000K	1000K	1000K	1000K	1000K	-1000K	-3.57M
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-84K	0	0	0	0	0	0	0	-100M	-201.21M
Other Financing	531K	1.91M	71K	567K	961K	-2.01M	1.43M	-4.97M	-2.02M	40.18M
Net Change in Cash	-20.52M▲ 0%	2.29M▲ 111.2%	22.75M▲ 891.5%	-9.87M▼ 143.4%	-7.79M▲ 21.0%	404.1M▲ 5287.4%	-234.2M▼ 158.0%	-51.66M▲ 77.9%	-54.4M▼ 5.3%	40.95M▲ 0%
Free Cash Flow	-114.81M▲ 0%	-78.19M▲ 31.9%	-146.49M▼ 87.4%	-150.65M▼ 2.8%	-103.32M▲ 31.4%	326.05M▲ 415.6%	55.58M▼ 83.0%	96.46M▲ 73.6%	60.16M▼ 37.6%	80.54M▲ 0%
FCF Margin %	-1039.64%	-23910.4%	-1786.87%	-427.76%	-221.96%	74.2%	7.69%	41.53%	21.7%	24.37%
FCF Growth %	-15.35%	31.9%	-87.36%	-2.84%	31.42%	415.56%	-82.95%	73.56%	-37.63%	255.26%
FCF per Share	-2.98	-1.49	-2.35	-2.09	-1.03	2.45	0.37	0.75	0.45	0.45
FCF Conversion (FCF/Net Income)	0.95x	0.81x	0.83x	0.79x	1.23x	4.37x	0.21x	-15.74x	2.44x	-1.86x
Interest Paid	0	0	0	0	16.54M	9.81M	5.64M	5.64M	5.64M	2.02M
Taxes Paid	0	0	0	0	0	1.31M	2.21M	2.01M	4.58M	2.6M

DVAX Key Ratios

Dynavax Technologies Corporation (DVAX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	TTM
Return on Equity (ROE)	-81.4%	-65.91%	-121.01%	-427.72%	-224.65%	54.59%	72.98%	-1.06%	4.48%	-8.13%
Return on Invested Capital (ROIC)	-80.15%	-60.54%	-79.98%	-67.55%	-26.28%	70.04%	62.49%	-4.07%	-0.42%	-0.42%
Gross Margin	100%	-265.14%	-165.87%	44.95%	70.12%	60.5%	63.73%	78.4%	82.17%	83.17%
Net Margin	-1018.24%	-29099.08%	-1938.27%	-433.29%	-161.63%	17.46%	40.56%	-2.75%	9.85%	-13.13%
Debt / Equity	-	-	1.60x	26.11x	3.71x	1.16x	0.44x	0.41x	0.43x	0.43x
Interest Coverage	-	-	-16.42x	-7.94x	-3.95x	12.03x	42.12x	-5.48x	-0.61x	-5.28x
FCF Conversion	0.95x	0.81x	0.83x	0.79x	1.23x	4.37x	0.21x	-15.74x	2.44x	-1.86x
Revenue Growth	172.67%	-97.04%	2407.03%	329.6%	32.18%	844%	64.45%	-67.86%	19.36%	26.73%

DVAX SEC Filings & Documents

Dynavax Technologies Corporation (DVAX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Feb 10, 2026·SEC

Material company update

Dec 29, 2025·SEC

Material company update

Nov 5, 2025·SEC

10-K Annual Reports

FY 2025

Feb 20, 2025·SEC

FY 2024

Feb 22, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 7, 2025·SEC

FY 2025

May 6, 2025·SEC

DVAX Frequently Asked Questions

Dynavax Technologies Corporation (DVAX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Dynavax Technologies Corporation (DVAX) reported $330.5M in revenue for fiscal year 2024. This represents a 23061% increase from $1.4M in 2002.

Dynavax Technologies Corporation (DVAX) grew revenue by 19.4% over the past year. This is strong growth.

Dynavax Technologies Corporation (DVAX) reported a net loss of $43.4M for fiscal year 2024.

Dividend & Returns

Dynavax Technologies Corporation (DVAX) has a return on equity (ROE) of 4.5%. This is below average, suggesting room for improvement.

Dynavax Technologies Corporation (DVAX) generated $80.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More DVAX

Dynavax Technologies Corporation (DVAX) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Dynavax Technologies Corporation(DVAX)Earnings, Financials & Key Ratios

DVAX Key Insights

✓Strengths

✗Weaknesses

DVAX Price & Volume

DVAX Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

DVAX Recent Earnings

DVAX Peer Comparison

Compare DVAX vs Peers

vs NVAX

vs MRK

Compare Top 5

DVAX Income Statement

DVAX Balance Sheet

DVAX Cash Flow Statement

DVAX Key Ratios

DVAX SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

DVAX Frequently Asked Questions

Explore More DVAX

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation